PROGRAMS TERMS AND CONDITIONS:

1. Next Tech Pathway
The Next Tech Pathway program (the “Program”) allows eligible, enrolled participants whose MiniMed^™ 670G system order is shipped starting on 11/7/19 to be included. The last day to place an order is 12/1/20. This Program allows for an upgrade to our next MiniMed^™ system at $0. Eligibility dates subject to change.

To be eligible for the Program, participants must purchase a MiniMed^™ 670G system and meet one of the following requirements:

• New to Medtronic insulin pump therapy
• Upgrade from an out-of-warranty

This program is not available to customers on a rental program such as those enrolled in federal, state, or other government-funded healthcare program like Medicare, Medicare Advantage, Medicaid, Medigap, the Department of Defense (“DoD”) or TRICARE.

To upgrade through the Program, all participants must agree and are subject to these terms and conditions:

• Return of old MiniMed^™ 670G insulin pump is required. If the old pump is not returned within 90 days, you will be charged $3,200.
• Replacement warranty period does not reset when you receive the new technology. The warranty period of an upgraded insulin pump and transmitter will remain the same as the warranty date of the initial pump and transmitter purchased.
• MiniMed^™ pumps have certain labeling restrictions that may exclude certain populations, including age and type of diabetes. We recommend you consult your healthcare provider.
• Upon first commercial shipping of a new MiniMed^™ system, it may take up to 90 days for Medtronic to contact you with the option to upgrade. Once you place your order, it may take up to 90 days to ship the new product. The Program does not guarantee prioritization of your order.
• An upgrade through the Program can only be redeemed once during your warranty period for the next available technology and customers’ order must ship no later than 4/1/21. The Program cannot be redeemed if less than six (6) months remains on your pump warranty.
• The Program for the future upgrade applies to one (1) in-warranty insulin pump and one (1) in-warranty transmitter. CGM sensors and consumables are not included, however, these Medtronic products will remain compatible.
• If transmitter is out of warranty, customer will need to purchase a new transmitter.
• Insurance coverage and plan design varies and may impact the ability to upgrade. Coverage is contingent upon your health insurance medical policy guidelines. Restrictions and medical necessity requirements may apply.
• A valid prescription will be required to purchase a new pump. All participants should consult their healthcare provider for all therapy related decisions.
• Program terms and conditions are subject to change at any time and without notice. Other restrictions may apply.

• $99 charge will be required upfront to use Lift Ticket. Return of old insulin pump is required. If old pump not returned, customer will be charged $3,200.
• After you have requested to use your Lift Ticket, it could take up to 60 days to process your order. The Lift Ticket Program does not guarantee prioritization of your order.
• Lift Ticket can only be redeemed once during your Replacement warranty period. A Lift Ticket cannot be redeemed if less than six (6) months remains on your pump warranty period.
• The Lift Ticket Program price applies to (1) insulin pump. CGM products and consumables are not included.
• Insurance coverage and approvals may impact patient ability to upgrade. Coverage for your pump is contingent upon your payer medical policy guidelines. Restrictions and medical necessity requirements apply.
• Warranty dates do not reset. The Replacement warranty date of an upgraded insulin pump will remain the same as the Replacement warranty date of the initial pump purchased.
• Patients enrolled in a rental program must complete their final payment and own their pump before utilizing the Lift Ticket program.
• MiniMed^™ pumps have certain labeling restrictions that may exclude certain populations, including age and type of diabetes. We recommend you consult your Healthcare Provider.
• A valid prescription will be required to purchase a new pump. Other restrictions may apply.
• Program terms and conditions are subject to change at any time and without notice.
• Any purchase for a patient with Out of Warranty pump or new to pump therapy of a Medtronic insulin pump that shipped between 11/14/18 and 4/11/19 is eligible to receive a Lift Ticket.

• Customers with more than six months remaining on their warranty are eligible for the Pathway Program.
• The Pathway Program is for pump upgrades only. CGM, if required or requested, must be purchased separately.
• The Pathway Program does not extend the Replacement warranty period. The customer’s current warranty timeline will not change by purchasing a pump through this program.
• Customers will need to verify that their payer will support transitioning to the new pump, as it could affect ongoing coverage of their future pump supplies.
• Customers must return their old pump within 30 days. Patients who do not return their pump will be charged $3,200.
• Pricing, terms, and conditions are subject to change at any time and without notice.
• $500 credit for Medtronic pump, Tandem^® pump, Animas^® pump, or Roche^® pump. $250 credit for Omnipod^® receiver.

• This program is only available for out-of-warranty MiniMed™ insulin pump customers
• Failure to return your old MiniMed™ pump will disqualify you for the $500 Pump Trade-in Program credit, and you will be responsible for the full cost of the Medtronic pump.

• A prescription from a healthcare provider for CGM therapy is required.
• Customers must have an in-warranty Guardian Connect transmitter.
• Customer must pay $200 for the new transmitter. Once the customer returns their Guardian Connect transmitter, and Medtronic will refund the $200.
• The following patient groups will not be eligible for the Transmitter Pathway Program:
o Patients who have no CGM coverage including Medicare, Medicaid, and other government payers
• Program terms and conditions are subject to change at any time and without notice.

• A prescription from a healthcare provider for CGM therapy is required.
• Customers must have an in-warranty transmitter.
• Customers will pay $300 out-of-pocket to purchase a Medtronic CGM transmitter and a (1) 5-pack of sensors.
• Upon receipt of payment, Medtronic will ship (1) transmitter and a (1) 5-pack of sensors.
• If patient returns their old transmitter to Medtronic, the patient will receive a $200 trade-in credit. The credit will be applied to their original payment method.
• If customer does not return your in-warranty transmitter, they will not receive a $200 credit back.
• The following patient groups will not be eligible for the Transmitter Pathway Program:
o Abbott Libre is a disposable CGM system. Therefore, these patients are not eligible o Patients who have no CGM coverage including Medicare, Medicaid, and other government payers
• Program terms and conditions are subject to change at any time and without notice.

Important Safety Information: MiniMed^™ 770G System With SmartGuard^™ Technology
The MiniMed^™ 770G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons two years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed^™ 770G System includes SmartGuard^™ technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitoring (CGM) sensor glucose (SG) values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.

The Medtronic MiniMed^™ 770G System consists of the following devices: MiniMed^™ 770G Insulin Pump, the Guardian^™ Link (3) Transmitter, the Guardian^™ Sensor (3), one-press serter, the Accu-Chek^® Guide Link blood glucose meter, and the Accu-Chek^® Guide Test Strips. The system requires a prescription.

The Guardian^™ Sensor (3) has not been evaluated and is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. All therapy adjustments should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian^™ Sensor (3).

All therapy adjustments should be based on measurements obtained using the Accu-Chek^® Guide Link blood glucose meter and not on values provided by the Guardian^™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the Accu-Chek^® Guide Link blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise.

WARNING: Do not use the SmartGuard^™ Auto Mode for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in SmartGuard^™ Auto Mode.

WARNING: Do not use the MiniMed^™ 770G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed^™ 770G system.

Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed^™ 770G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult https://www.medtronicdiabetes.com/important-safety-information#minimed-770g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library

Important Safety Information: MiniMed^™ 670G System
The Medtronic MiniMed^™ 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, seven years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed^™ 670G system includes SmartGuard^™ technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values. The system requires a prescription. The Guardian^™ Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. A confirmatory finger stick test via the CONTOUR^®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. All therapy adjustments should be based on measurements obtained using the CONTOUR^®NEXT LINK 2.4 blood glucose meter and not on values provided by the Guardian^™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR^®NEXT LINK 2.4 blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an Alternative Site (palm) or from a control solution test. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode.

WARNING: Medtronic performed an evaluation of the MiniMed^™ 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.

Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 670G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult http://www.medtronicdiabetes.com/important-safety-information#minimed-670g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library

Important Safety Information: Guardian^™ Connect CGM System
The Guardian^™ Connect system requires a prescription and is indicated for continuous or periodic monitoring of glucose levels in the interstitial fluid under the skin, in patients (14 to 75 years of age) with diabetes mellitus. The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices, and is not recommended for people who are unwilling or unable to perform a minimum of two meter blood glucose tests per day, or for people who are unable or unwilling to maintain contact with their healthcare professional. The system requires a functioning mobile electronic device with correct settings. If the mobile device is not set up or used correctly, you may not receive sensor glucose information or alerts. For complete details of the system and its components, including warnings, contraindications, and precautions, please consult the user guide at http://www.medtronicdiabetes.com/support/download-library/user-guides and important safety information.